Interferon-alpha (IFNα) was once the standard of frontline treatment for chronic myeloid
leukemia (CML). Its pleiotropic mechanism of action in CML includes immune activation and …

Abstract Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …

Biological agents have long been used in the treatment of cancer, and interferon-alpha was
the first human cytokine to be widely studied in this setting. Chronic myeloid leukemia (CML) …

Treatment of chronic myeloid leukemia (CML) with interferon-alpha (IFN-α) was introduced
in the early 1980s. Several clinical trials showed a survival advantage for patients treated …

The cytokine interferon-alfa (IFN-α) has substantial activity in chronic myeloid leukemia
(CML) and is the nontransplant standard of care for chronic-phase disease. When used as …

Imatinib has revolutionized the therapy of chronic myeloid leukaemia. However the complete
eradication of leukaemic stem cells is still a matter of discussion. Interferon (IFN) has been …

Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for
chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML …

Management decisions for patients with chronic myeloid leukemia (CML) have become
remarkably complex due to a variety of highly effective treatment options. Therapy for …

Purpose Imatinib induces sustained remissions in patients with chronic myelogenous
leukemia (CML), but fails to eradicate CML stem cells. This is of major concern regarding the …

Background Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have …